WHO Digital Documentation of COVID-19 Certificates (DDCC)
1.0.0 - CI Build International flag

This is the continuous build for version 1.0.0. This version is based on the current content of https://github.com/WorldHealthOrganization/ddcc and changes regularly.

ValueSet: Vaccine - COVID-19 - CVX (Experimental)

Official URL: http://smart.who.int/ddcc/ValueSet/vaccine-covid19-cvx Version: 1.0.0
Draft as of 2024-04-24 Computable Name: VaccineCovid19CvxValueSet

This is a one-time snapshot of the allowed CVX codes for vaccines, retrieved in February 2023. Contents may need to be updated and readers should consult the credential documentation, found here http://hl7.org/fhir/uv/shc-vaccination/2021Sep/ValueSet-vaccine-cvx.html. More information on the CVX value set can be found here, https://www2a.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=cvx

References

This value set is not used here; it may be used elsewhere (e.g. specifications and/or implementations that use this content)

Logical Definition (CLD)

  • Include these codes as defined in http://hl7.org/fhir/sid/cvx
    CodeDisplay
    207COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose
    208COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose
    210COVID-19 vaccine, vector-nr, rS-ChAdOx1, PF, 0.5 mL
    211COVID-19, subunit, rS-nanoparticle+Matrix-M1 Adjuvant, PF, 0.5 mL
    212COVID-19 vaccine, vector-nr, rS-Ad26, PF, 0.5 mL
    213SARS-COV-2 (COVID-19) vaccine, UNSPECIFIED
    217COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose
    218COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose
    219COVID-19, mRNA, LNP-S, PF, 3 mcg/0.2 mL dose, tris-sucrose
    221COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL dose
    225COVID-19, D614, recomb, preS dTM, AS03 adjuvant add, PF, 5mcg/0.5mL
    226COVID-19, D614, recomb, preS dTM, AS03 adjuvant add, PF, 10mcg/0.5mL
    227COVID-19, mRNA, LNP-S, PF, pediatric 50 mcg/0.5 mL dose
    228COVID-19, mRNA, LNP-S, PF, pediatric 25 mcg/0.25 mL dose
    229COVID-19, mRNA, LNP-S, bivalent booster, PF, 50 mcg/0.5 mL or 25mcg/0.25 mL dose
    230COVID-19, mRNA, LNP-S, bivalent booster, PF, 10 mcg/0.2 mL
    300COVID-19, mRNA, LNP-S, bivalent booster, PF, 30 mcg/0.3 mL dose
    301COVID-19, mRNA, LNP-S, bivalent booster, PF, 10 mcg/0.2 mL dose
    302COVID-19, mRNA, LNP-S, bivalent, PF, 3 mcg/0.2 mL dose
    500COVID-19 Non-US Vaccine, Product Unknown
    501COVID-19 IV Non-US Vaccine (QAZCOVID-IN)
    502COVID-19 IV Non-US Vaccine (COVAXIN)
    503COVID-19 LAV Non-US Vaccine (COVIVAC)
    504COVID-19 VVnr Non-US Vaccine (Sputnik Light)
    505COVID-19 VVnr Non-US Vaccine (Sputnik V)
    506COVID-19 VVnr Non-US Vaccine (CanSino Biological Inc./Beijing Institute of Biotechnology)
    507COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom Biopharm + Inst of Micro, Chinese Acad of Sciences)
    508COVID-19 PS Non-US Vaccine (Jiangsu Province Centers for Disease Control and Prevention)
    509COVID-19 PS Non-US Vaccine (EpiVacCorona)
    510COVID-19 IV Non-US Vaccine (BIBP, Sinopharm)
    511COVID-19 IV Non-US Vaccine (CoronaVac, Sinovac)
    512SARS-COV-2 COVID-19 VLP Non-US Vaccine (Medicago, Covifenz)
    513SARS-COV-2 COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom, Zifivax)
    514SARS-COV-2 COVID-19 DNA Non-US Vaccine (Zydus Cadila, ZyCoV-D)
    515SARS-COV-2 COVID-19 PS Non-US Vaccine (Medigen, MVC-COV1901)
    516COV-2 COVID-19 Inactivated Non-US Vaccine Product (Minhai Biotechnology Co, KCONVAC)
    517SARS-COV-2 COVID-19 PS Non-US Vaccine (Biological E Limited, Corbevax)
    518COVID-19 Inactivated, Non-US Vaccine (VLA2001, Valneva)
    519COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine (Spikevax Bivalent), Moderna
    520COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine Product, Pfizer-BioNTech

 

Expansion

This value set contains 40 concepts

Expansion based on:

  • codesystem http://hl7.org/fhir/sid/cvx version 20231214
  • system http://hl7.org/fhir/sid/cvx version 20231214
CodeSystemDisplay
  207http://hl7.org/fhir/sid/cvxCOVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose
  208http://hl7.org/fhir/sid/cvxCOVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose
  210http://hl7.org/fhir/sid/cvxCOVID-19 vaccine, vector-nr, rS-ChAdOx1, PF, 0.5 mL
  211http://hl7.org/fhir/sid/cvxCOVID-19, subunit, rS-nanoparticle+Matrix-M1 Adjuvant, PF, 0.5 mL
  212http://hl7.org/fhir/sid/cvxCOVID-19 vaccine, vector-nr, rS-Ad26, PF, 0.5 mL
  213http://hl7.org/fhir/sid/cvxSARS-COV-2 (COVID-19) vaccine, UNSPECIFIED
  217http://hl7.org/fhir/sid/cvxCOVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose
  218http://hl7.org/fhir/sid/cvxCOVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose
  219http://hl7.org/fhir/sid/cvxCOVID-19, mRNA, LNP-S, PF, 3 mcg/0.2 mL dose, tris-sucrose
  221http://hl7.org/fhir/sid/cvxCOVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL dose
  225http://hl7.org/fhir/sid/cvxCOVID-19, D614, recomb, preS dTM, AS03 adjuvant add, PF, 5mcg/0.5mL
  226http://hl7.org/fhir/sid/cvxCOVID-19, D614, recomb, preS dTM, AS03 adjuvant add, PF, 10mcg/0.5mL
  227http://hl7.org/fhir/sid/cvxCOVID-19, mRNA, LNP-S, PF, pediatric 50 mcg/0.5 mL dose
  228http://hl7.org/fhir/sid/cvxCOVID-19, mRNA, LNP-S, PF, pediatric 25 mcg/0.25 mL dose
  229http://hl7.org/fhir/sid/cvxCOVID-19, mRNA, LNP-S, bivalent, PF, 50 mcg/0.5 mL or 25mcg/0.25 mL dose
  230http://hl7.org/fhir/sid/cvxCOVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL
  300http://hl7.org/fhir/sid/cvxCOVID-19, mRNA, LNP-S, bivalent, PF, 30 mcg/0.3 mL dose
  301http://hl7.org/fhir/sid/cvxCOVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL dose
  302http://hl7.org/fhir/sid/cvxCOVID-19, mRNA, LNP-S, bivalent, PF, 3 mcg/0.2 mL dose
  500http://hl7.org/fhir/sid/cvxCOVID-19 Non-US Vaccine, Product Unknown
  501http://hl7.org/fhir/sid/cvxCOVID-19 IV Non-US Vaccine (QAZCOVID-IN)
  502http://hl7.org/fhir/sid/cvxCOVID-19 IV Non-US Vaccine (COVAXIN)
  503http://hl7.org/fhir/sid/cvxCOVID-19 LAV Non-US Vaccine (COVIVAC)
  504http://hl7.org/fhir/sid/cvxCOVID-19 VVnr Non-US Vaccine (Sputnik Light)
  505http://hl7.org/fhir/sid/cvxCOVID-19 VVnr Non-US Vaccine (Sputnik V)
  506http://hl7.org/fhir/sid/cvxCOVID-19 VVnr Non-US Vaccine (CanSino Biological Inc./Beijing Institute of Biotechnology
  507http://hl7.org/fhir/sid/cvxCOVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom Biopharm + Inst of Micro, Chinese Acad of Sciences)
  508http://hl7.org/fhir/sid/cvxCOVID-19 PS Non-US Vaccine (Jiangsu Province Centers for Disease Control and Prevention)
  509http://hl7.org/fhir/sid/cvxCOVID-19 PS Non-US Vaccine (EpiVacCorona)
  510http://hl7.org/fhir/sid/cvxCOVID-19 IV Non-US Vaccine (BIBP, Sinopharm)
  511http://hl7.org/fhir/sid/cvxCOVID-19 IV Non-US Vaccine (CoronaVac, Sinovac)
  512http://hl7.org/fhir/sid/cvxSARS-COV-2 COVID-19 VLP Non-US Vaccine (Medicago, Covifenz)
  513http://hl7.org/fhir/sid/cvxSARS-COV-2 COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom, Zifivax)
  514http://hl7.org/fhir/sid/cvxSARS-COV-2 COVID-19 DNA Non-US Vaccine (Zydus Cadila, ZyCoV-D)
  515http://hl7.org/fhir/sid/cvxSARS-COV-2 COVID-19 PS Non-US Vaccine (Medigen, MVC-COV1901)
  516http://hl7.org/fhir/sid/cvxCOV-2 COVID-19 Inactivated Non-US Vaccine Product (Minhai Biotechnology Co, KCONVAC)
  517http://hl7.org/fhir/sid/cvxSARS-COV-2 COVID-19 PS Non-US Vaccine (Biological E Limited, Corbevax)
  518http://hl7.org/fhir/sid/cvxCOVID-19 Inactivated, Non-US Vaccine (VLA2001, Valneva)
  519http://hl7.org/fhir/sid/cvxCOVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine (Spikevax Bivalent), Moderna
  520http://hl7.org/fhir/sid/cvxCOVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine Product, Pfizer-BioNTech

Explanation of the columns that may appear on this page:

Level A few code lists that FHIR defines are hierarchical - each code is assigned a level. In this scheme, some codes are under other codes, and imply that the code they are under also applies
System The source of the definition of the code (when the value set draws in codes defined elsewhere)
Code The code (used as the code in the resource instance)
Display The display (used in the display element of a Coding). If there is no display, implementers should not simply display the code, but map the concept into their application
Definition An explanation of the meaning of the concept
Comments Additional notes about how to use the code